Tesaro (TSRO) PT Lowered to $76 at Wedbush

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Tesaro (TSRO) PT Lowered to $76 at Wedbush

TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results

February 27, 2018 4:05 PM EST

ZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S.2017 ZEJULA® net sales totaled $109 million during first nine months of commercial launchFocused clinical development program for niraparib in ovarian cancer is advancing in first-line and platinum-resistant settingsMultiple immuno-oncology clinical studies to read out in 2018Enrollment of registration trial of TSR-042 (anti-PD-1 mAb) to complete by YE 2018

WALTHAM, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company,... More